A Biopharmaceutical Leader in
Placental Therapeutic and Regenerative Biologics


allografts distributed


reported adverse reactions


issued patents


peer-reviewed publications

MiMedx® is a biopharmaceutical company developing, manufacturing and marketing regenerative biologics utilizing human placental allografts for multiple sectors of healthcare. To date, over 40 clinical and scientific papers have been published in peer-reviewed journals on our amniotic tissue-based technologies. The Company’s extensive product portfolio is covered by over 45 issued patents, with more than 90 patents pending. Our PURION®, PURION® Plus, and LyoPur™ Processed allografts are clinically effective, and more than 1,000,000 allografts have been distributed to date with zero reported adverse reactions attributed to our products.*

For more information, visit: www.mimedx.com

*As of August 1, 2017